Page 2 - கடுமையான முதலீட்டாளர் உறவுகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

(0) 7MBq dose of Radspherin determined to be safe, and approved by the SMC as the recommended clinical dose for repeated injection and expansion cohorts of RAD-18-002 study Oncoinvent AS, a clinical stage company advancing a pipeline of radiopharmaceutical products across a variety of solid cancers, today announced that the Safety Monitoring Committee for the RAD-18-002 clinical trial has concluded that the 7 MBq dose of Radspherin to be safe and has approved initiation of the repeated injection and expansion cohorts of the ongoing RAD-18-002 Phase 1 study in colorectal cancer patients suffering from peritoneal carcinomatosis. Radspherin, an a-emitting radionuclide therapy designed for treatment of metastatic cancers in body cavities, is also being evaluated in an ongoing Phase 1 study in ovarian cancer patients with peritoneal carcinomatosis.

Jana alfheimCourtney turianoKostenloser wertpapierhandelMbq radspherinSafety monitoring committeeLinear energy transferChief executive officerChief financial officerStern investor relationsபாதுகாப்பு கண்காணிப்பு குழுநேரியல் ஆற்றல் பரிமாற்றம்தலைமை நிர்வாகி அதிகாரிதலைமை நிதி அதிகாரிகடுமையான முதலீட்டாளர் உறவுகள்